Sirius Genomics Announces Appointment of Senior Director of Business Development

VANCOUVER, June 30 /CNW/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that Kamran Alam has been appointed Senior Director of Business Development.

"Sirius Genomics is on track with our existing products and looking to grow our pipeline. Kam's extensive background in partnering with both global pharmaceutical and medical device companies as well as experience in building collaborations with academic and translational research centers will support our commercialization initiatives and product pipeline development," stated Chris Wagner, President and CEO of Sirius Genomics.

Mr. Alam has over 12 years experience in the biotech and medical device industry, during which time he has worked in several therapeutic areas in the roles of Business Development and Finance. Prior to joining Sirius Genomics, Mr. Alam held positions in business development at the Centre for Drug Research and Development, Angiotech Pharmaceuticals, and AnorMED Inc., and has successfully completed numerous and varied partnering deals, mergers and acquisitions, licensing transactions, and has executed extensive business development initiatives in the U.S., Europe and Asia.

Mr. Alam's professional experience also includes roles with PricewaterhouseCoopers LLP Chartered Accountants. A member of the Institute of Chartered Accountants of British Columbia, Mr. Alam holds an MBA Degree, specializing in International Business and Strategy, and a Bachelor of Science Degree, specializing in Cell Biology and Genetics.

About Sirius Genomics: www.siriusgenomics.com

Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

For further information: Chris Wagner, President and CEO, Sirius Genomics, 604-484-7195